Pear Therapeutics, Inc. (PEAR)
Pear Therapeutics, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $4.1M. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of -187.0%. Its beta of 0.52 implies it has historically moved less than the broad market.
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Pear Therapeutics, Inc. is most often compared with the following Healthcare names: